Open AccessIs an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?
Author(s) -
Kei Kunimasa,
Kazumi Nishino,
Toru Kumagai
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.02.18
Subject(s) - lung cancer , medicine , cancer research , chemotherapy , cancer , immune checkpoint , mutant , immune system , immunotherapy , targeted therapy , mutation , oncology , immunology , biology , gene , biochemistry